A multicentre, single-arm phase II trial of adagrasib in patients with KRASG12C-mutant NSCLC, including the elderly (≥70 years) or patients with poor performance status.

ADEPPT: Adagrasib in patients with KRASG12C-mutant NSCLC who are elderly or have poor performance status

The aim of the trial is to assess the clinical efficacy of adagrasib treatment, in terms of objective response, in patients with KRASG12C‑mutant NSCLC, including the elderly (≥70 years) or patients with poor performance status (ECOG PS=2). 

Trial Scheme

USZ STRIKE trial schema


Primary Endpoint: Objective Response Rate (ORR) per RECIST v1.1, assessed at 12 weeks
Secondary Endpoints:

Durable clinical benefit

Time to progression

Progression-free Survival

Overall Survival


Patient-related outcomes

Target Sample Size: 68 enrolled patients
Protocol Release Date: 15 July 2022

Trial Organisation

Trial Chair: Jarushka Naidoo, Dublin, Ireland
Trial Co-Chairs:

Colin Lindsay, Manchester, United Kingdom

Bartomeu Massuti, Alicante, Spain

Sponsor: ETOP IBCSG Partners Foundation
Coordinating Group:

ETOP IBCSG Partners Foundation

Participating Groups:

Cancer Trials Ireland (CTI) and the Spanish Lung Cancer Group (SLCG) 

Participating Countries:   

Belgium, France, Ireland, Italy, Spain, and United Kingdom


EudraCT number: 2022-002736-31

clinicaltrials.gov:  NCT05673187


Virginia Rodriguez Martinez (Clinical Trial Manager)

This email address is being protected from spambots. You need JavaScript enabled to view it.


ETOP IBCSG Partners Foundation

Effingerstrasse 33

3008 Bern, Switzerland